Modeling Cancer Metabolism: from the Generic to the Personalized

Livnat Jerby




30/11/11

Outline

- Why study the metabolism of cancer?
- How can we study metabolism in-silico?
- Three approaches to study cancer metabolism:
 - **1.** Generic cancer metabolic model (MSB, Folger. et al 2011)
 - 2. Cancer type-specific metabolic model (Nature, Frezza et al. 2011)
 - 3. Personalized metabolic model

Treating Cancer is Challenging

- The improvement in treating cancer is slow
- Cancer metabolism has been neglected
- Interest in cancer metabolism is resurging



Cancer Metabolism is Aberrant

- Warburg Effect- anaerobic respiration
- Why should the metabolism of cancer be altered?
 - The tumor microenvironment
 - Oncogene activation
 - Avoiding apoptosis
 - Proliferation




Upper arm metastasis shows high glucose consumption

The constantly beating heart is the only healthy tissue with high glucose consumption

Ovarian cancer shows high glucose consumption

How Can We Model Metabolism?




Constraint Based Modeling: the Underlying Framework


- A genome-scale approach to model metabolism
- Predict the flux rate of metabolic reactions
- Allows in-silico simulation
- Successfully used in microbiology and biotechnology
- The first human genome-scale metabolic model (Duarte et al. 2007)


The First Genome-scale Metabolic Model of Cancer


- Human metabolic model
- Add a biomass reaction simulates growth.
- Identify cancer reactions
- Applied Model Building Algorithm (MBA) (Jerby et al. 2008)
- Approximation of cancer metabolism

Jerby, L., T. Shlomi, and E. Ruppin, *Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism.* Mol Syst Biol, 2010. **6**.











Computationally Identify Synthetic Lethal Pairs





Computationally Identify Synthetic Lethal Pairs



Additional information

Computationally Identify Synthetic Lethal Pairs






Synthetic Lethal Pairs as Potential Personalized Anticancer Therapy


Fallopian tube carcinoma Esophageal carcinoma Head and neck SCC Non-small cell lung cancer Thymic carcinoma Cervical carcinoma Prostate cancer Nasopharyngeal carcinoma Anal carcinoma Wilms' tumor Bladder carcinoma Barrett"s adenocarcinoma Nerve sheath tumor Pancreatic cancer Thyroid carcinoma, follicular Renal cell carcinoma Bile duct carcinoma Hepatocellular carcinoma Adrenocortical carcinoma Small cell lung cancer Neuroendocrine luna tumor Uterine/cervix carcinoma Colorectal carcinoma Parathyroid adenoma

Cancer Types




FH-deficient renal cancer

- Mutations in the metabolic gene Fumarate hydratase (FH) cause renal cancer
- Constructed a specific metabolic model of this cancer type
- FH found synthetically lethal with HMOX



HLRCC: Synthetic Lethality Validation




Personalized


"No disease suffered by a live man can be known, for every living person has his own novel, complicated disease, unknown to medicine"

Tolstoy

Method: Metabolic Profiling Analysis (MPA)



Phenotype Prediction Based on MPA Metabolic Profiles



- Conventional features gene expression
- MPA replaces those with the metabolic profiles
- Metabolic profile
 - lipid metabolism
 - amino-acids biosynthesis

Thanks!

Ori Folger (Tel Aviv University), my colleague.

Christian Frezza and Prof. Eyal Gottlieb (Beatson Institute, Glasgow), our experimental collaborators.

Prof. Lior Wolf (Tel Aviv University)

Dr. Tomer Shlomi (Technion Institute)

Prof. Eytan Ruppin (Tel Aviv University), my research advisors.

Contact : livnatje@post.tau.ac.il



THANKYOU

Questions?